263 related articles for article (PubMed ID: 22802243)
21. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].
Aliamovskaia GA; Keshinian ES
Vestn Ross Akad Med Nauk; 2012; (12):30, 32-4. PubMed ID: 23530423
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
[TBL] [Abstract][Full Text] [Related]
23. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
[TBL] [Abstract][Full Text] [Related]
24. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
25. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
[TBL] [Abstract][Full Text] [Related]
26. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ
Cochrane Database Syst Rev; 2014 May; (5):CD007743. PubMed ID: 24851825
[TBL] [Abstract][Full Text] [Related]
27. Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study.
Torchin H; Rousseau J; Marchand-Martin L; Truffert P; Jarreau PH; Ancel PY
Arch Pediatr; 2018 Feb; 25(2):89-94. PubMed ID: 29395887
[TBL] [Abstract][Full Text] [Related]
28. Prevention of respiratory syncytial virus infection with palivizumab.
Thomas M; Bedford-Russell A; Sharland M
Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
[TBL] [Abstract][Full Text] [Related]
29. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
Fenton C; Scott LJ; Plosker GL
Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
[TBL] [Abstract][Full Text] [Related]
30. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
31. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
32. Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model.
Saadah LM; Chedid FD; Sohail MR; Nazzal YM; Al Kaabi MR; Rahmani AY
Pharmacotherapy; 2014 Mar; 34(3):251-9. PubMed ID: 23897635
[TBL] [Abstract][Full Text] [Related]
33. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
35. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
Groothuis JR; Nishida H
Pediatr Int; 2002 Jun; 44(3):235-41. PubMed ID: 11982888
[TBL] [Abstract][Full Text] [Related]
36. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
[TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
38. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
[TBL] [Abstract][Full Text] [Related]
39. Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus.
Makari D; Checchia PA; Devincenzo J
Hum Vaccin Immunother; 2014; 10(3):607-14. PubMed ID: 24316863
[TBL] [Abstract][Full Text] [Related]
40. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.
Simões EA; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick L; Groothuis JR;
J Allergy Clin Immunol; 2010 Aug; 126(2):256-62. PubMed ID: 20624638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
